RxDoctor Payments Data

Alicia Hamman

Family · Decatur, ALNPI 1497278246

Payments from drug & device makers

$963in general payments, 2019–2025

Across 49 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$299
  • AbbVie$121
  • Paratek Pharmaceuticals, Inc.$118
  • AstraZeneca$101
  • Lilly USA, LLC$96
  • Abbott$56
  • plus $171 from 6 others

What the payments were for

  • Food & beverage$963100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$963 in reported general payments places this provider in the 65th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$64,804
Medicare patients
125
Services billed
1,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$41,927
TrulicityDulaglutide41$38,597
EliquisApixaban40$29,747
FarxigaDapagliflozin Propanediol23$27,275
JardianceEmpagliflozin18$13,726
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,515
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$10,268
Clonidine14$2,224
Levothyroxine Sodium170$2,013
Albuterol Sulfate HfaAlbuterol Sulfate36$1,777
Metoprolol Succinate118$1,696
Rosuvastatin Calcium71$1,663
Hydroxychloroquine Sulfate28$1,626
Omeprazole109$1,608
Esomeprazole Magnesium25$1,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$299$41,92736 claims
Lilly USA, LLCTrulicity$96$38,59741 claims
AstraZenecaFarxiga, Breztri Aerosphere$101$37,54335 claims
PfizerEliquis$55$29,74740 claims
GSKTrelegy Ellipta$15$11,51518 claims
AbbVieSynthroid$121$1,38717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,415 family providers in Alabama.

Other family in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →